coin-img-ETHETH+0.26%coin-img-BTCBTC+0.55%coin-img-SOLSOL+1.09%coin-img-ROBOROBO-0.04%coin-img-KATKAT-1.06%coin-img-AITOAITO-29.51%coin-img-CRKCRK-40.05%coin-img-USDCUSDC+0.02%coin-img-ETHETH+0.26%coin-img-BTCBTC+0.55%coin-img-SOLSOL+1.09%coin-img-ROBOROBO-0.04%coin-img-KATKAT-1.06%coin-img-AITOAITO-29.51%coin-img-CRKCRK-40.05%coin-img-USDCUSDC+0.02%coin-img-ETHETH+0.26%coin-img-BTCBTC+0.55%coin-img-SOLSOL+1.09%coin-img-ROBOROBO-0.04%coin-img-KATKAT-1.06%coin-img-AITOAITO-29.51%coin-img-CRKCRK-40.05%coin-img-USDCUSDC+0.02%coin-img-ETHETH+0.26%coin-img-BTCBTC+0.55%coin-img-SOLSOL+1.09%coin-img-ROBOROBO-0.04%coin-img-KATKAT-1.06%coin-img-AITOAITO-29.51%coin-img-CRKCRK-40.05%coin-img-USDCUSDC+0.02%
user-avatar
Tim Fries

ImmunityBio (IBRX) rises March 17, 2026 after NCCN adds ANKTIVA to 2026 guidelines

ImmunityBio (NASDAQ: IBRX) climbed 6.82% in premarket trading to $8.77 on March 17, 2026 after the NCCN updated its 2026 bladder cancer guidelines to include ANKTIVA plus BCG for certain BCG-unresponsive NMIBC patients. The change expands NCCN guidance beyond prior references centered on carcinoma in situ (CIS), while ANKTIVA’s current FDA label remains limited to CIS with or without papillary tumors following its April 2024 approval.
Descargo de responsabilidad: El contenido anterior es solo la opinión del autor y no representa la postura de BingX. No debe interpretarse como un consejo de inversión por parte de BingX. Para obtener más información, consulta los Términos y condiciones.